Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide

Robert E.J. Ryder; Katharina Laubner; Marek Benes; Martin Haluzik; Lynne Munro; Harry Frydenberg; Julian P. Teare; Aruchuna Ruban; Sigal Fishman; Erwin Santo; Rainer Stengel; Charlotte De Jonge; Jan W. Greve; Ricardo V. Cohen; Cristina M. Aboud; Gerald J. Holtmann; Graeme Rich; Jess J. McMaster; Tadej Battelino; Primoz Kotnik; James P. Byrne; John C. Mason; Justin Bessell; Jeanine Bascomb; Lillian Kow; Janes Collins; Jacob Chisholm; Peter N. Pferschy; Harald Sourij; Melissa L. Cull; Melanie C. Wyres; Russell Drummond; Barbara McGowan; Stephanie A. Amiel; Mahi Yadagiri; Piya Sen Gupta; Jens Aberle; Jochen Seufert

doi:10.2337/dc22-1952

Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide

Robert E.J. Ryder, Katharina Laubner, Marek Benes, Martin Haluzik, Lynne Munro, Harry Frydenberg, Julian P. Teare, Aruchuna Ruban, Sigal Fishman, Erwin Santo, Rainer Stengel, Charlotte De Jonge, Jan W. Greve, Ricardo V. Cohen, Cristina M. Aboud, Gerald J. Holtmann, Graeme Rich, Jess J. McMaster, Tadej Battelino, Primoz KotnikJames P. Byrne, John C. Mason, Justin Bessell, Jeanine Bascomb, Lillian Kow, Janes Collins, Jacob Chisholm, Peter N. Pferschy, Harald Sourij, Melissa L. Cull, Melanie C. Wyres, Russell Drummond, Barbara McGowan, Stephanie A. Amiel, Mahi Yadagiri, Piya Sen Gupta, Jens Aberle, Jochen Seufert

Research output: Contribution to journal › Letter › peer-review

11 Citations (Scopus)

Abstract

There is a worldwide pandemic of type 2 diabetes (T2D) and obesity (1). In clinical practice, many patients with obesity have poor glycemic management despite diet and lifestyle advice and maximal medications (2–4). In this situation, Roux-en-Y gastric bypass is highly effective, and increased use of bariatric surgery has been recommended (2). Nevertheless, it is an invasive and irreversible surgical procedure. EndoBarrier (GI Dynamics, Boston, MA), also known as duodenal-jejunal bypass liner, is a 60-cm impermeable fluoropolymer sleeve that is implanted endoscopically into the upper part of the small intestine (2–4), left in place for up to 1 year, and then removed endoscopically. The duodenal-jejunal bypass liner was developed to mimic the proposed small-bowel mechanisms of Roux-en-Y gastric bypass (2–4) while being less invasive. In Europe in 2017, approval for use (certificate of Conformité Européenne, or CE mark) of EndoBarrier was not renewed for reasons that are not entirely clear (3,4). As over 3,000 patients have been treated with EndoBarrier worldwide, during 2017, an independent, secure, online registry was established by the Association of British Clinical Diabetologists (ABCD) for the collection of safety and efficacy data of EndoBarrier-treated patients worldwide.

Original language	English
Pages (from-to)	e89-e91
Number of pages	3
Journal	Diabetes care
Volume	46
Issue number	4
Early online date	30 Jan 2023
DOIs	https://doi.org/10.2337/dc22-1952
Publication status	Published - Apr 2023
Externally published	Yes

Keywords

Diabetes
Obesity
Risk factor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2337/dc22-1952Licence: In Copyright

Cite this

Ryder, R. E. J., Laubner, K., Benes, M., Haluzik, M., Munro, L., Frydenberg, H., Teare, J. P., Ruban, A., Fishman, S., Santo, E., Stengel, R., De Jonge, C., Greve, J. W., Cohen, R. V., Aboud, C. M., Holtmann, G. J., Rich, G., McMaster, J. J., Battelino, T., ... Seufert, J. (2023). Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide. Diabetes care, 46(4), e89-e91. https://doi.org/10.2337/dc22-1952

@article{2a34ab5bd9ee40ba9ada4968f97b88b1,

title = "Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide",

abstract = "There is a worldwide pandemic of type 2 diabetes (T2D) and obesity (1). In clinical practice, many patients with obesity have poor glycemic management despite diet and lifestyle advice and maximal medications (2–4). In this situation, Roux-en-Y gastric bypass is highly effective, and increased use of bariatric surgery has been recommended (2). Nevertheless, it is an invasive and irreversible surgical procedure. EndoBarrier (GI Dynamics, Boston, MA), also known as duodenal-jejunal bypass liner, is a 60-cm impermeable fluoropolymer sleeve that is implanted endoscopically into the upper part of the small intestine (2–4), left in place for up to 1 year, and then removed endoscopically. The duodenal-jejunal bypass liner was developed to mimic the proposed small-bowel mechanisms of Roux-en-Y gastric bypass (2–4) while being less invasive. In Europe in 2017, approval for use (certificate of Conformit{\'e} Europ{\'e}enne, or CE mark) of EndoBarrier was not renewed for reasons that are not entirely clear (3,4). As over 3,000 patients have been treated with EndoBarrier worldwide, during 2017, an independent, secure, online registry was established by the Association of British Clinical Diabetologists (ABCD) for the collection of safety and efficacy data of EndoBarrier-treated patients worldwide.",

keywords = "Diabetes, Obesity, Risk factor",

author = "Ryder, {Robert E.J.} and Katharina Laubner and Marek Benes and Martin Haluzik and Lynne Munro and Harry Frydenberg and Teare, {Julian P.} and Aruchuna Ruban and Sigal Fishman and Erwin Santo and Rainer Stengel and {De Jonge}, Charlotte and Greve, {Jan W.} and Cohen, {Ricardo V.} and Aboud, {Cristina M.} and Holtmann, {Gerald J.} and Graeme Rich and McMaster, {Jess J.} and Tadej Battelino and Primoz Kotnik and Byrne, {James P.} and Mason, {John C.} and Justin Bessell and Jeanine Bascomb and Lillian Kow and Janes Collins and Jacob Chisholm and Pferschy, {Peter N.} and Harald Sourij and Cull, {Melissa L.} and Wyres, {Melanie C.} and Russell Drummond and Barbara McGowan and Amiel, {Stephanie A.} and Mahi Yadagiri and Gupta, {Piya Sen} and Jens Aberle and Jochen Seufert",

year = "2023",

month = apr,

doi = "10.2337/dc22-1952",

language = "English",

volume = "46",

pages = "e89--e91",

journal = "Diabetes care",

issn = "0149-5992",

publisher = "AMERICAN DIABETES ASSOCIATION",

number = "4",

}

Ryder, REJ, Laubner, K, Benes, M, Haluzik, M, Munro, L, Frydenberg, H, Teare, JP, Ruban, A, Fishman, S, Santo, E, Stengel, R, De Jonge, C, Greve, JW, Cohen, RV, Aboud, CM, Holtmann, GJ, Rich, G, McMaster, JJ, Battelino, T, Kotnik, P, Byrne, JP, Mason, JC, Bessell, J, Bascomb, J, Kow, L, Collins, J, Chisholm, J, Pferschy, PN, Sourij, H, Cull, ML, Wyres, MC, Drummond, R, McGowan, B, Amiel, SA, Yadagiri, M, Gupta, PS, Aberle, J & Seufert, J 2023, 'Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide', Diabetes care, vol. 46, no. 4, pp. e89-e91. https://doi.org/10.2337/dc22-1952

TY - JOUR

T1 - Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity

T2 - Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide

AU - Ryder, Robert E.J.

AU - Laubner, Katharina

AU - Benes, Marek

AU - Haluzik, Martin

AU - Munro, Lynne

AU - Frydenberg, Harry

AU - Teare, Julian P.

AU - Ruban, Aruchuna

AU - Fishman, Sigal

AU - Santo, Erwin

AU - Stengel, Rainer

AU - De Jonge, Charlotte

AU - Greve, Jan W.

AU - Cohen, Ricardo V.

AU - Aboud, Cristina M.

AU - Holtmann, Gerald J.

AU - Rich, Graeme

AU - McMaster, Jess J.

AU - Battelino, Tadej

AU - Kotnik, Primoz

AU - Byrne, James P.

AU - Mason, John C.

AU - Bessell, Justin

AU - Bascomb, Jeanine

AU - Kow, Lillian

AU - Collins, Janes

AU - Chisholm, Jacob

AU - Pferschy, Peter N.

AU - Sourij, Harald

AU - Cull, Melissa L.

AU - Wyres, Melanie C.

AU - Drummond, Russell

AU - McGowan, Barbara

AU - Amiel, Stephanie A.

AU - Yadagiri, Mahi

AU - Gupta, Piya Sen

AU - Aberle, Jens

AU - Seufert, Jochen

PY - 2023/4

Y1 - 2023/4

N2 - There is a worldwide pandemic of type 2 diabetes (T2D) and obesity (1). In clinical practice, many patients with obesity have poor glycemic management despite diet and lifestyle advice and maximal medications (2–4). In this situation, Roux-en-Y gastric bypass is highly effective, and increased use of bariatric surgery has been recommended (2). Nevertheless, it is an invasive and irreversible surgical procedure. EndoBarrier (GI Dynamics, Boston, MA), also known as duodenal-jejunal bypass liner, is a 60-cm impermeable fluoropolymer sleeve that is implanted endoscopically into the upper part of the small intestine (2–4), left in place for up to 1 year, and then removed endoscopically. The duodenal-jejunal bypass liner was developed to mimic the proposed small-bowel mechanisms of Roux-en-Y gastric bypass (2–4) while being less invasive. In Europe in 2017, approval for use (certificate of Conformité Européenne, or CE mark) of EndoBarrier was not renewed for reasons that are not entirely clear (3,4). As over 3,000 patients have been treated with EndoBarrier worldwide, during 2017, an independent, secure, online registry was established by the Association of British Clinical Diabetologists (ABCD) for the collection of safety and efficacy data of EndoBarrier-treated patients worldwide.

AB - There is a worldwide pandemic of type 2 diabetes (T2D) and obesity (1). In clinical practice, many patients with obesity have poor glycemic management despite diet and lifestyle advice and maximal medications (2–4). In this situation, Roux-en-Y gastric bypass is highly effective, and increased use of bariatric surgery has been recommended (2). Nevertheless, it is an invasive and irreversible surgical procedure. EndoBarrier (GI Dynamics, Boston, MA), also known as duodenal-jejunal bypass liner, is a 60-cm impermeable fluoropolymer sleeve that is implanted endoscopically into the upper part of the small intestine (2–4), left in place for up to 1 year, and then removed endoscopically. The duodenal-jejunal bypass liner was developed to mimic the proposed small-bowel mechanisms of Roux-en-Y gastric bypass (2–4) while being less invasive. In Europe in 2017, approval for use (certificate of Conformité Européenne, or CE mark) of EndoBarrier was not renewed for reasons that are not entirely clear (3,4). As over 3,000 patients have been treated with EndoBarrier worldwide, during 2017, an independent, secure, online registry was established by the Association of British Clinical Diabetologists (ABCD) for the collection of safety and efficacy data of EndoBarrier-treated patients worldwide.

KW - Diabetes

KW - Obesity

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=85151043009&partnerID=8YFLogxK

U2 - 10.2337/dc22-1952

DO - 10.2337/dc22-1952

M3 - Letter

C2 - 36716004

AN - SCOPUS:85151043009

SN - 0149-5992

VL - 46

SP - e89-e91

JO - Diabetes care

JF - Diabetes care

IS - 4

ER -

Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this